182 related articles for article (PubMed ID: 32807114)
41. Elevated neutrophil to lymphocyte ratio predicts poor prognosis in patients with non-small cell lung cancer after surgery.
Ju X; Zheng L; Niu Y; Guan H; Luo H
Asian J Surg; 2020 Sep; 43(9):940-941. PubMed ID: 32522378
[No Abstract] [Full Text] [Related]
42. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
[TBL] [Abstract][Full Text] [Related]
43. Survival predictors in advanced non-small cell lung cancer.
Hespanhol V; Queiroga H; Magalhães A; Santos AR; Coelho M; Marques A
Lung Cancer; 1995 Dec; 13(3):253-67. PubMed ID: 8719065
[TBL] [Abstract][Full Text] [Related]
44. Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy.
Gonzalez G; Crombet T; Torres F; Catala M; Alfonso L; Osorio M; Neninger E; Garcia B; Mulet A; Perez R; Lage R
Ann Oncol; 2003 Mar; 14(3):461-6. PubMed ID: 12598354
[TBL] [Abstract][Full Text] [Related]
45. Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.
Mendell J; Freeman DJ; Feng W; Hettmann T; Schneider M; Blum S; Ruhe J; Bange J; Nakamaru K; Chen S; Tsuchihashi Z; von Pawel J; Copigneaux C; Beckman RA
EBioMedicine; 2015 Mar; 2(3):264-71. PubMed ID: 26137564
[TBL] [Abstract][Full Text] [Related]
46. Can blood-based markers predict RECIST progression in non-small cell lung cancer treated with immunotherapy?
Yeghaian M; Tareco Bucho TM; de Bruin M; Schmitz A; Bodalal Z; Smit EF; Beets-Tan RGH; van den Broek D; Trebeschi S
J Cancer Res Clin Oncol; 2024 Jun; 150(6):329. PubMed ID: 38922374
[TBL] [Abstract][Full Text] [Related]
47. Effectiveness and safety of chemotherapy with cytokine-induced killer cells in non-small cell lung cancer: A systematic review and meta-analysis of 32 randomized controlled trials.
Xiao Z; Wang CQ; Feng JH; Zhou MH; Wang YZ; Li NN; Sun YP; Liu SY; Yao XS; Li CW; Ma B; Ding J; Chen L
Cytotherapy; 2019 Feb; 21(2):125-147. PubMed ID: 30554868
[TBL] [Abstract][Full Text] [Related]
48. Blood serum proteins as biomarkers for prediction of survival, locoregional control and distant metastasis rate in radiotherapy and radio-chemotherapy for non-small cell lung cancer.
Suwinski R; Giglok M; Galwas-Kliber K; Idasiak A; Jochymek B; Deja R; Maslyk B; Mrochem-Kwarciak J; Butkiewicz D
BMC Cancer; 2019 May; 19(1):427. PubMed ID: 31068179
[TBL] [Abstract][Full Text] [Related]
49. Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
Buttigliero C; Shepherd FA; Barlesi F; Schwartz B; Orlov S; Favaretto AG; Santoro A; Hirsh V; Ramlau R; Blackler AR; Roder J; Spigel D; Novello S; Akerley W; Scagliotti GV
Oncologist; 2019 Jun; 24(6):e251-e259. PubMed ID: 30139835
[TBL] [Abstract][Full Text] [Related]
50. Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer.
Zheng H; Liu X; Zhang J; Rice SJ; Wagman M; Kong Y; Zhu L; Zhu J; Joshi M; Belani CP
Oncotarget; 2016 Aug; 7(35):56233-56240. PubMed ID: 27191652
[TBL] [Abstract][Full Text] [Related]
51. Increased CD8+CD28+ T cells independently predict better early response to stereotactic ablative radiotherapy in patients with lung metastases from non-small cell lung cancer.
Liu C; Hu Q; Hu K; Su H; Shi F; Kong L; Zhu H; Yu J
J Transl Med; 2019 Apr; 17(1):120. PubMed ID: 30971280
[TBL] [Abstract][Full Text] [Related]
52. Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer.
Neninger E; Verdecia BG; Crombet T; Viada C; Pereda S; Leonard I; Mazorra Z; Fleites G; González M; Wilkinson B; González G; Lage A
J Immunother; 2009 Jan; 32(1):92-9. PubMed ID: 19307998
[TBL] [Abstract][Full Text] [Related]
53. Prognostic Value of White Blood Cells Detected for the First Time After Adjuvant Chemotherapy in Primary Operable Non-Small Cell Lung Cancer.
Hao L; Zhang J; Di Y; Tan Z
Technol Cancer Res Treat; 2018 Jan; 17():1533033818802813. PubMed ID: 30295143
[TBL] [Abstract][Full Text] [Related]
54. Neutrophil-to-lymphocyte ratio is superior to platelet-to-lymphocyte ratio as a prognostic predictor in advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy.
Guo D; Li M; Chen D; Jing W; Zhu H; Fu L; Kong L; Yue J; Yu J
Future Oncol; 2019 Feb; 15(6):625-635. PubMed ID: 30430864
[TBL] [Abstract][Full Text] [Related]
55. Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor.
Inomata M; Kado T; Okazawa S; Imanishi S; Taka C; Kambara K; Hirai T; Tanaka H; Tokui K; Hayashi K; Miwa T; Hayashi R; Matsui S; Tobe K
Anticancer Res; 2019 Dec; 39(12):6887-6893. PubMed ID: 31810958
[TBL] [Abstract][Full Text] [Related]
56. Predictive and prognostic value of preoperative serum tumor markers is EGFR mutation-specific in resectable non-small-cell lung cancer.
Jiang R; Wang X; Li K
Oncotarget; 2016 May; 7(18):26823-36. PubMed ID: 27072585
[TBL] [Abstract][Full Text] [Related]
57. Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.
Althammer S; Tan TH; Spitzmüller A; Rognoni L; Wiestler T; Herz T; Widmaier M; Rebelatto MC; Kaplon H; Damotte D; Alifano M; Hammond SA; Dieu-Nosjean MC; Ranade K; Schmidt G; Higgs BW; Steele KE
J Immunother Cancer; 2019 May; 7(1):121. PubMed ID: 31060602
[TBL] [Abstract][Full Text] [Related]
58. [Research Advances in CIMAvax-EGF for Non-small-cell Lung Cancer].
Zhang JY; Zhu L; Yang HK; Chen F
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2018 Jun; 40(3):411-414. PubMed ID: 29978802
[TBL] [Abstract][Full Text] [Related]
59. Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
de Jong C; Deneer VHM; Kelder JC; Ruven H; Egberts TCG; Herder GJM
Thorac Cancer; 2020 Jul; 11(7):1790-1800. PubMed ID: 32383328
[TBL] [Abstract][Full Text] [Related]
60. Prognostic Significance of Serum miR-22, miR-125b, and miR-15b in Non-Small Cell Lung Cancer Patients.
Shi GL; Zhang XY; Chen Y; Ma S; Bai WQ; Yin YJ
Clin Lab; 2020 Jun; 66(6):. PubMed ID: 32538046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
